Y Intercept Hong Kong Ltd Purchases New Shares in Lantheus Holdings, Inc. $LNTH

Y Intercept Hong Kong Ltd acquired a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 75,382 shares of the medical equipment provider’s stock, valued at approximately $3,866,000. Y Intercept Hong Kong Ltd owned approximately 0.11% of Lantheus at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Assenagon Asset Management S.A. purchased a new stake in shares of Lantheus in the third quarter valued at about $65,654,000. Polaris Capital Management LLC bought a new stake in Lantheus in the 3rd quarter worth about $32,687,000. Norges Bank purchased a new stake in Lantheus in the 2nd quarter valued at about $32,631,000. Galvin Gaustad & Stein LLC bought a new position in shares of Lantheus during the 2nd quarter worth approximately $11,899,000. Finally, Boston Partners lifted its position in shares of Lantheus by 30.5% during the 2nd quarter. Boston Partners now owns 576,362 shares of the medical equipment provider’s stock worth $46,432,000 after buying an additional 134,781 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Up 0.5%

Shares of NASDAQ LNTH opened at $67.51 on Monday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49. The stock has a market capitalization of $4.48 billion, a PE ratio of 28.37 and a beta of -0.11. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $111.29. The business’s fifty day moving average price is $63.52 and its 200-day moving average price is $60.26.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, November 6th. The medical equipment provider reported $1.27 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.27. The business had revenue of $384.01 million for the quarter, compared to analysts’ expectations of $363.42 million. Lantheus had a return on equity of 30.88% and a net margin of 10.99%.The firm’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the business posted $1.70 EPS. Lantheus has set its FY 2025 guidance at 5.500-5.650 EPS. On average, equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on LNTH shares. Mizuho upped their target price on Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. The Goldman Sachs Group set a $77.00 price objective on Lantheus and gave the company a “neutral” rating in a research note on Wednesday, October 8th. Truist Financial lifted their target price on Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Finally, Weiss Ratings raised shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Five equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $78.00.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.